Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00
Provider: Wright Reports
$357.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

IntegraGen announces study showing relationship between survival time without progression and expression of microARN hsa-miR-31-3p in patients treated with anti-EGFR therapy


Thursday, 15 May 2014 02:59am EDT 

IntegraGen SA:Announces publication of study showing relationship between survival time without progression and expression of microARN hsa-miR-31-3p in primary tumour in patients with metastatic colorectal cancer without KRAS (KRAS WT) mutation and treated with anti-EGFR therapy.Study shows that survival time without progression becomes shorter as level of miR-31-3p expression becomes higher.Intragen has exclusive worldwide rights to miR-31-3p biomarker. 

Company Quote

5.41
-0.08 -1.46%
21 Jul 2014